NCT04551053 2025-10-02To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)Incyte CorporationPhase 3 Terminated177 enrolled 15 charts
NCT01773187 2020-09-29Pacritinib Versus Best Available Therapy to Treat MyelofibrosisCTI BioPharmaPhase 3 Terminated327 enrolled 11 charts
NCT00324324 2017-05-09Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell TransplantOHSU Knight Cancer InstitutePhase 3 Terminated240 enrolled
NCT01650805 2014-11-17Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)Ariad PharmaceuticalsPhase 3 Terminated307 enrolled 11 charts
NCT00089141 2013-05-03Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)Fred Hutchinson Cancer CenterPhase 3 Terminated151 enrolled 17 charts